Skip to main content
Malec L, Carcao M, Mathias M, Kragh N, Dumont J, Willemze A, Bystricka L, Wilson A, DiBenedetti D. Experiences with efanesoctocog alfa: exit interviews with caregivers of previously treated patients with hemophilia a from the XTEND-Kids phase 3 clinical trial. Presentation to be given at the 65th ASH Annual Meeting & Exposition 2023; December 10, 2023. San Diego, CA.
Handels R, Wimo A, Skoldunger A, Tate A, Winblad B, Silvertand D, Nguyen L, Jonsson L, Grimm S, Aye S, Herring W. Open-source model framework for health-economic evaluation of early treatment in Alzheimer's disease. Presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark.
Boeri M, Heidenreich S, Cappelleri JC, Vass C, Mt-Isa S, Necdet G, Robert V, Garczarek U, Saint-hilary G, Colopy M, Krucien N, Sepulveda JMG. Sample size decisions for discrete choice experiments in pharmaceutical and health care applications. Presented at the SMDM 45th Annual North American Meeting; October 23, 2023. Philadelphia, PA.
Barbieri M, Senese F, Mellott CE, Boccalini S, Carrico J, Bechini A, Talbird SE, Chen Y-H, Bencina G. Public health impact and return on investment of the pediatric national immunization program in Italy. Presented at the Italian Society of Hygiene, Preventive Medicine, and Public Health Conference; October 12, 2023. Cernobbio, Italy.
Thomsen RW, Andersen IT, Kristensen FP, Munch PV, Pladevall-Vila M, Johannes C, Saigi-Morgui N, Ziemiecki R, Layton J, Vizcaya D, Gay A, Farjat A, Liu F, Oberprieler N, Christiansen CF. Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and type 2 diabetes in Denmark: a nationwide population-based study part of the FOUNTAIN platform. Presented at the 59th Annual Meeting European Association for the Study of Diabetes (EASD) 2023; October 4, 2023. Hamburg, Germany.
Moehler M, Wyrwicz L, Blum S, Chen C, Wang J, Davenport E, Nathani R, Kondo K, Elimova E. Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer(GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C). Presented at the ESMO World Congress on Gastrointestinal Cancer 2023; June 28, 2023. Barcelona, Spain.
Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L, Chevalier J, Gaudin AF, Roupret M, Branchoux S. Impact of method for modelling distant recurrence (DR) on cost-effectiveness (CE) of nivolumab (NIVO) as an adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) patients with high risk of recurrence in France. Presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.